Trial Profile
Extension Study Evaluating Treatment With Pf-05280586 Versus Rituximab In Subjects With Active Rheumatoid Arthritis Who Have Participated In Other Pf-05280586 Clinical Trials
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Acronyms REFLECTIONS B328-04
- Sponsors Pfizer
- 11 Apr 2016 Planned number of patients changed from 157 to 184.
- 11 Apr 2016 Status changed from active, no longer recruiting to completed.
- 21 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.